Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million

Reuters11-13

Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million

Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101 (anti-TL1A) and is on track to initiate a Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574171-en) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583915588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583915588","market":"nz","top_or_hot":-1,"title":"Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101 (anti-TL1A) and is on track to initiate a Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574171-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci reports Q3 revenue of $0.4 million and net loss of $28.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101 (anti-TL1A) and is on track to initiate a Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574171-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7LYS1q:1","article_id":"2583915588","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583915588","pubTimestamp":1762981636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101  and is on track to initiate a Phase 1/2a trial for ABS-201  in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4539":"次新股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ABSI":"Absci Corporation.","BK4121":"生命科学工具和服务","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Absci报告第三季度收入为40万美元，净亏损为2870万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ABSI":0.9},"content_text":"Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million\n    \n\n        Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101 (anti-TL1A) and is on track to initiate a Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574171-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583915588","isCrawlerRequest":true}